Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Prolia therapy for postmenopausal women with osteoporosis

June 3, 2010

Novo Nordisk to soon launch Victoza in Japan

June 3, 2010

FDA accepts Qnexa NDA for obesity for review

June 2, 2010

Genfit receives approval for two IT-Diab trials in France

June 2, 2010

Phase II trial of BCX-4208 with or without allopurinol initiated in gout

June 2, 2010

Wyeth Europa notifies EMA of withdrawal of MAA for Brilence

June 1, 2010

FDA committee recommends approval of tesamorelin

May 31, 2010

Prolia obtains marketing authorization in E.U.

May 31, 2010

NICE issues recommendation for somatropin products, including Omnitrope

May 31, 2010

Galderma claims new melanocortin MC4 receptor antagonists

May 31, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...